Literature DB >> 1528956

"Clinical Global Impressions" (ECDEU): some critical comments.

M Beneke1, W Rasmus.   

Abstract

Following experience with several clinical trials, the semantic, logical, and statistical properties of the Clinical Global Impressions Scale (CGI-ECDEU, 1976; CIPS, 1986) were investigated. It was concluded that the CGI in its present version (a) may induce inconsistent rating behavior, (b) contains redundant information, (c) consists of items which exhibit extremely abnormal distribution properties. Furthermore (d), some of these items are inappropriately constructed or (e) cast some doubts on their significance as measurements. It is suggested that item #1 (seriousness of disease) be used at the beginning of a study only, and that item #2 (global improvement) be used sparingly and as single measurement to express the doctor's general impression. There would seem to be no basis for the judgment of a pure drug effect (item #3). The instruction to measure improvement by comparing the patient's present condition to that at admission to the study cannot be recommended. Poor distribution properties and a presumably restricted significance of change ratings suggest that parametric statistics should not be referred to.

Entities:  

Mesh:

Year:  1992        PMID: 1528956     DOI: 10.1055/s-2007-1014401

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  15 in total

1.  The clinical global impressions scale: applying a research tool in clinical practice.

Authors:  Joan Busner; Steven D Targum
Journal:  Psychiatry (Edgmont)       Date:  2007-07

2.  Assessing Clinical Improvement in School-Based Treatment for Social Anxiety Disorder: Agreement Between Adolescents, Parents, and Independent Evaluators.

Authors:  Jeremy K Fox; Carrie Masia Warner
Journal:  Child Psychiatry Hum Dev       Date:  2017-10

Review 3.  Long-acting medications for the hyperkinetic disorders. A note on cost-effectiveness.

Authors:  Michael Schlander
Journal:  Eur Child Adolesc Psychiatry       Date:  2007-10       Impact factor: 4.785

Review 4.  Outcome measures in intervention trials for adults with autism spectrum disorders; a systematic review of assessments of core autism features and associated emotional and behavioural problems.

Authors:  Traolach S Brugha; Lucy Doos; Althea Tempier; Stewart Einfeld; Patricia Howlin
Journal:  Int J Methods Psychiatr Res       Date:  2015-06       Impact factor: 4.035

5.  Increasing the Sensitivity of Measures to Change.

Authors:  Carlotta Ching Ting Fok; David Henry
Journal:  Prev Sci       Date:  2015-10

6.  Psychometric validation of the child health questionnaire (CHQ) in a sample of children and adolescents with attention-deficit/hyperactivity disorder.

Authors:  Anne M Rentz; Louis S Matza; Kristina Secnik; Andrine Swensen; Dennis A Revicki
Journal:  Qual Life Res       Date:  2005-04       Impact factor: 4.147

7.  Clinical response in a risperidone-medicated naturalistic sample: patients' characteristics and dose-dependent pharmacokinetic patterns.

Authors:  Michael Paulzen; Ekkehard Haen; Benedikt Stegmann; Stefan Unterecker; Christoph Hiemke; Gerhard Gründer; Georgios Schoretsanitis
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-10-01       Impact factor: 5.270

8.  Vulnerability in clinical research with patients in pain: a risk analysis.

Authors:  Raymond C Tait
Journal:  J Law Med Ethics       Date:  2009       Impact factor: 1.718

9.  Patient-assessed versus physician-assessed disease severity and outcome in patients with nonspecific pain associated with major depressive disorder.

Authors:  Koen Demyttenaere; Durisala Desaiah; Claude Petit; Jens Croenlein; Stephan Brecht
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009

10.  The Clinical Global Impression Scale and the influence of patient or staff perspective on outcome.

Authors:  Thomas Forkmann; Anne Scherer; Maren Boecker; Markus Pawelzik; Ralf Jostes; Siegfried Gauggel
Journal:  BMC Psychiatry       Date:  2011-05-14       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.